Calculating the impact of central corneal thickness on IOP levels through correction algorithms appears to not affect the prevalence of open-angle glaucoma, but CCT remains an important risk factor for the disease, a study found.

The number of mast cells in glaucoma patients was significantly higher in those who had previous trabeculectomy than those who had not. This could possibly be associated with an increased risk of excessive conjunctival scarring after surgery.

Data gathered in a prospective study support the practice of providing maximum hypermetropic correction in children with fully accommodative esotropia

TORONTO — Occulogix subsidiary OcuSense has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for clearance to market its TearLab Osmolarity System and the TearLab Osmolarity Test Card in the United States, according to a press release from Occulogix.

IRVINE, Calif. — Ista Pharmaceuticals posted a net loss of $7.4 million, or $0.22 per share, for the third quarter, compared with a net loss of $8.2 million, or $0.25 per share, for the same period in 2007, the company announced.

Investigators found fixation preference testing did not accurately identify children with two lines or more of interocular difference.

MONROVIA, Calif. — STAAR Surgical reported $18.1 million in total product sales for the third quarter, representing a 33% increase compared with $13.6 million during the third quarter of 2007, the company announced in a press release.

AMITYVILLE, N.Y. — The U.S. Food and Drug Administration has approved Hi-Tech Pharmacal's abbreviated new drug application for dorzolamide hydrochloride and timolol maleate ophthalmic solution, the company announced in a press release.

EXTON, Pa. — The U.S. Patent and Trademark Office has issued Othera Pharmaceuticals the first patent covering a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation involved in age-related macular degeneration and other ocular disorders.

PRINCETON, N.J. — Ophthotech has enrolled the first patient in a phase 1 clinical trial of ARC1905, an anti-C5 complement factor aptamer being developed to treat age-related macular degeneration, the company announced in a press release.